Medtronic Gets FDA OK for Inceptiv Closed-Loop Spinal Cord Stimulator
By Colin Kellaher
Medtronic has won Food and Drug Administration approval of its Inceptiv closed-loop rechargeable spinal cord stimulator, or SCS, to treat chronic pain.
Medtronic on Friday said Inceptiv is its first SCS device to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts stimulation in real time.
The Dublin-based company said Inceptiv adjusts for movements such as laughing, bending or sneezing that can result in brief moments of uncomfortable overstimulation from traditional fixed-output SCS devices, which in turn may lead some patients to turn down their device's stimulation output.
Medtronic plans to initiate the U.S. market launch of Inceptiv, which was previously approved for sale in Europe and Japan, in the coming weeks.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 26, 2024 08:56 ET (12:56 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening In the Markets This Week
-
What Does Nvidia’s Stock Split Mean for Investors?
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
Markets Brief: Friday’s Job Report in Focus
-
These Stocks Are (Still) Powering the Bull Market
-
Nio Earnings: Revenue and Loss Largely In Line, but Vehicle Margin Missed Amid Price Competition
-
The Best Biotech Stocks to Buy
-
After Earnings, Is Marvell Stock a Buy, a Sell, or Fairly Valued?
-
Nvidia Raised Its Dividend — but There’s a Catch
-
Lululemon Earnings: On Track to Meet Expectations Despite Slowdown In Americas
-
What Is Driving Small-Cap Stock Underperformance?
-
After Earnings, Is Zscaler Stock a Buy, a Sell, or Fairly Valued?
-
ASML Fair Value Raised as Outlook Improves